Qiagen and Bristol-Myers Squibb announce immuno-oncology alliance

Qiagen has announced a new collaboration with Bristol-Myers Squibb that will leverage next-generation sequencing (NGS) technology in the field of immuno-oncology.

The work will explore the use of NGS technology to develop gene expression profiles as predictive or prognostic tools for use with Bristol-Myers Squibb's novel immuno-oncology therapies in the treatment of cancer.

This will combine the breadth of Bristol-Myers Squibb's portfolio of immuno-oncology drugs with Qiagen's track record in developing and commercialising companion and complementary diagnostics, as well as its robust library of NGS technologies.

Gene expression profiles for several Bristol-Myers Squibb molecules will be developed initially, with subsequent work to develop diagnostic products based on these profiles.

Peer Schatz, chief executive officer of Qiagen, said: "Our teams at Qiagen are looking forward to working with Bristol-Myers Squibb to leverage the power of NGS technology to potentially improve outcomes for patients."

The two companies have been partnering since 2009, receiving US regulatory approval for their Therascreen KRAS companion/complementary diagnostic assay in 2012.

With over 20 years of experience within the science market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current science roles we have available, you can search for the latest job roles, register your details, or contact the team today.